Physiological and cytokine responses in IL-1β-deficient mice after zymosan-induced inflammation

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 273, Issue 1 42-1, 1997, Pages

  Fantuzzi, Giamila ^a   Sacco, Silvano ^b   Ghezzi, Pietro ^b   Dinarello, Charles A ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Acute phase response; Complement; Interleukin 6; Tumor necrosis factor

Indexed keywords

CYTOKINE; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR; ZYMOSAN;

ACUTE PHASE RESPONSE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CELL SURVIVAL; COMPLEMENT ACTIVATION; CONTROLLED STUDY; GENETIC TRANSDUCTION; HYPOGLYCEMIA; INFLAMMATION; MOUSE; NONHUMAN; PERITONEUM LAVAGE; PRIORITY JOURNAL; RECEPTOR BLOCKING; RESPIRATORY DISTRESS SYNDROME; SACCHAROMYCES CEREVISIAE; SPLEEN CELL;

EID: 0030795791     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.1997.273.1.r400     Document Type: Article

References (33)

1. Aggarwal, B. B., and K. Natarajan. Tumor necrosis factors: developments during the last decacde. Eur. Cytokine Netw. 7: 93-124, 1996.
2. Belmont, H. M., P. Hopkins, H. S. Edelson, H. B. Kaplan, R. Ludewig, G. Weissmann, and S. Abramson. Complement activation during systemic lupus erythematosus: C3a and C5a anaphylatoxins circulate during exacerbations of disease. Arthritis Rheum. 29: 1085-1089, 1986.
3. Beutler, B., and A. Cerami. Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature 320: 584-588, 1986.
4. Coligan, J. E., A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober. Current Protocols in Immunology. In Vitro Assays for Mouse Lymphocyte Function. New York: Wiley, 1992, vol. 1.
5. Collins, P. D., P. J. Jose, and T. J. Williams. The sequential generation of neutrophil chemoattractant proteins in acute inflammation in the rabbit in vivo. Relationship between C5a and proteins with the characteristics of IL-8/neutrophil-activating protein 1. J. Immunol. 146: 677-684, 1990.
6. Czop, J. K. Phagocytosis of particulate activators of the alternative complement pathway: effect of fibronectin. Adv. Immunol. 38: 361-398, 1986.
7. Deaver, D. R. A new non-isotopic detection system for immunoassays. Nature 377: 758-760, 1995.
8. Dinarello, C. A. Biological basis for interleukin-1 in disease. Blood 87: 2095-2147, 1996.
9. Duchateau, J., M. Haas, H. Schreyen, L. Radoux, I. Sprangers, F. X. Noel, M. Braun, and M. Lamy. Complement activation in patients at risk of developing the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 130: 1058-1064, 1984.
10. Fantuzzi, G., and C. A. Dinarello. The inflammatory response in interleukin-1β-deficient mice: comparison with other cytokine-related knock-out mice. J. Leukoc. Biol. 59: 489-493, 1996.
11. Fantuzzi, G., E. Di Santo, S. Sacco, F. Benigni, and P. Ghezzi. Role of the hypothalamus-pituitary-adrenal axis in the regulation of TNF production in mice. Effect of stress and inhibition of endogenous glucocorticoids. J. Immunol. 155: 3552-3555, 1995.
12. Fantuzzi, G., H. Zheng, R. Faggioni, F. Benigni, P. Ghezzi, J. D. Sipe, A. R. Shaw, and C. A. Dinarello. Effect of endotoxin in interleukin-1β-deficient mice. J. Immunol. 157: 291-296, 1996.
13. Forrest, M. J., P. J. Jose, and T. J. Williams. Kinetics of the generation and action of chemical mediators in zymosan-induced inflammation in the rabbit peritoneal cavity. Br. J. Pharmacol. 89: 719-730, 1986.
14. Frank, M. M., and L. F. Fries. The role of complement in inflammation and phagocytosis. Immunol. Today 12: 322-326, 1991.
15. Geiger, T., H. Towbin, A. Cosenti-Vargas, O. Zingel, J. Arnold, C. Rordorf, M. Glatt, and K. Vosbeck. Neutralization of interleukin-1β activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice and prevents the associated acute-phase response. Clin. Exp. Rheumatol. 11: 515-522, 1993.
16. Goris, R. J. A., W. K. F. Boekholtz, I. P. T. van Bebber, J. K. S. Nuytinck, and P. H. M. Schillings. Multiple-organ failure and sepsis without bacteria. An experimental model. Arch. Surg. 121: 897-901, 1986.
17. Heideman, M., and T. E. Hugli. Anaphylatoxin generation in multisystem organ failure. J. Trauma 24: 1038-1043, 1984.
18. Karkar, A. M., Y. Koshino, S. J. Cashman, A. C. Dash, J. Bonnefoy, A. Meager, and A. J. Rees. Passive immunization against tumour necrosis factor-alpha (TNF-alpha) and IL-1 beta protects from LPS enhancing injury in nephrotoxic nephritis in rats. Clin. Exp. Immunol. 90: 312-318, 1992.
19. Klemm, P., H. J. Harris, and M. Perretti. Effect of rolipram in a murine model of acute inflammation: comparison with the corticoid dexamethasone. Eur. J. Pharmacol. 281: 69-74, 1995.
20. Kozak, W., H. Zheng, C. A. Conn, D. Soszynski, L. H. T. Van der Ploeg, and M. J. Kluger. Thermal and behavioral effects of lipopolysaccharide and influenza in interleukin-1β-deficient mice. Am. J. Physiol. 269 (Regulatory Integrative Comp. Physiol. 38): R969-R977, 1995.
21. Malaviya, R., T. Ikeda, E. Ross, and S. N. Abraham. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-α. Nature 381: 77-80, 1996.
22. Mulligan, M. S., E. Schmid, B. Beck-Schimmer, G. O. Till, H. P. Friedl, R. B. Brauer, T. E. Hugli, M. Miyasaka, R. L. Warner, K. J. Johnson, and P. A. Ward. Requirement and role of C5a in acute lung inflammatory injury in rats. J. Clin. Invest. 98: 503-512, 1996.
23. Nieuwehuijzen, G. A. P., M. P. D. Meyer, T. Hendriks, and R. J. A. Goris. Deficiency of complement factor C5 reduces early mortality but does not prevent organ damage in an animal model of multiple organ dysfunction syndrome. Crit. Care Med. 23: 1686-1693, 1995.
24. Perretti, M., E. Solito, and L. Parente. Evidence that endogenous interleukin-1 is involved in leukocyte migration in acute experimental inflammation in rats and mice. Agents Actions 35: 71-78, 1992.
25. Petit, F., G. J. Bagby, and C. H. Lang. Tumor necrosis factor mediates zymosan-induced increase in glucose flux and insulin resistance. Am. J. Physiol. 268 (Endocrinol. Metab. 31): E219-E228, 1995.
26. Rao, T. S., J. L. Currie, A. F. Shaffer, and P. C. Isakson. In vivo characterization of zymosan-induced mouse peritoneal inflammation. J. Pharmacol. Exp. Ther. 269: 917-925, 1994.
27. Shornick, L. P., P. De Togni, S. Mariathasan, J. Goellner, J. Strauss-Schoenberger, R. W. Karr, T. A. Ferguson, and D. D. Chaplin. Alice deficient in IL-1β manifest impaired contact hypersensitivity to trinitrochlorobenzene. J. Exp. Med. 183: 1427-1436, 1996.
28. Smedegard, G., L. Cui, and T. E. Hugli. Endotoxin-induced shock in the rat. A role for C5a. Am. J. Pathol. 135: 489-497, 1989.
29. Van de Loo, F. A. J., L. A. B. Joosten, P. L. E. M. van Lent, O. J.-Arntz, and W. B. van der Berg. Role of interleukin-1, tumor necrosis factor α, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum. 38: 164-172, 1995.
30. Van der Berg, W. B., L. A. Joosten, M. Helsen, and F. A. van de Loo. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin. Exp. Immunol. 95: 237-243, 1994.
31. Von Asmuth, E. J. U., J. G. Maessen, C. J. Van der Linden, and W. A. Buurman. Tumour necrosis factor alpha (TNF-α) and interleukin 6 in a zymosan-induced shock model. Scand. J. Immunol. 32: 313-319, 1990.
32. Weinberg, P. F., M. A. Matthay, R. O. Webster, K. V. Roskos, I. M. Glodstein, and J. F. Murray. Biologically active products of complement and acute lung injury in patients with the sepsis syndrome. Am. Rev. Respir. Dis. 130: 791-796, 1984.
33. Zheng, H., D. Fletcher, W. Kozak, M. Jiang, K. Hofmann, C. A. Conn, D. Soszynski, C. Grabiec, M. E. Trumbauer, A. Shaw, M. J. Kostura, K. Stevens, H. Rosen, R. J. North, H. Y Chen, M. J. Tocci, M. J. Kluger, and L. H. T. Van der Ploeg. Resistance to fever induction and impaired acute-phase response in interleukin-1β deficient mice. Immunity 3: 9-19, 1995.